Reportstack

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) ? Opportunity Analysis and Forecasts to 2017 - Event-Driven Update

 

Naperville, IL -- (ReleaseWire) -- 02/25/2014 -- Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) ? Opportunity Analysis and Forecasts to 2017 - Event-Driven Update market report to its offering
The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.

Scope

Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.

Analysis of the current and future market competition in the global NASH therapeutics market.

Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist.

Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market.

Reasons To Buy

Develop business strategies and perform superior market quantification analysis by:

Understanding the trends shaping and driving the global NASH Therapeutics market.

Understanding treatment preferences of physicians in disease state and across treatment flow.

Accessing market sizing, forecasts and quantified growth opportunities in the global NASH Therapeutics market till 2017.

Quantifying patient population in the global NASH Therapeutics market to better design product pricing & launch plans.

Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

Performing benchmarking analysis and growth opportunities against currently marketed products.

Identifying market entry points based on safety, efficacy, and pricing parameters.

Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

Develop and design your in-licensing and out-licensing strategies by

Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

Assessing strength of pipeline based on first in class and lifecycle management of products.

Analyze the potential impact of novel oral therapies such as Genfit’s GFT505 on the NASH treatment paradigm.

Track drug sales in the global NASH Therapeutics market from 2012 to 2017.

Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

What’s the next big thing in the global NASH Therapeutics market landscape? Identify, understand, and capitalize

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/150724/opportunityanalyzer-nonalcoholic-steatohepatitis-nash-opportunity-analysis-and-forecasts-to-2017-event-driven-update.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###